ImageneBio, Inc. (IMA)
ImageneBio, Inc. (IMA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.
As of Oct 23, 2026: market cap $52.4M; returns 1 day +4.3%, 1 week +4.5%, 1 year -42.9%.
ImageneBio, Inc. (NASDAQ: IMA) is a clinical-stage biotechnology company primarily focused on developing differentiated therapies for immunological and inflammatory (I&I) diseases. The company was formed in July 2025 through the merger of Ikena Oncology, Inc. and Inmagene Biopharmaceuticals, subsequently adopting the ImageneBio name and ticker symbol.
Groups IMA belongs to
- Biotechnology
- Healthcare
- Biopharmaceutical
- Clinical Stage
- Clinical Stage Biotech
- Autoimmune Diseases
- Chronic Inflammatory Diseases
- Dermatology
- Monoclonal Antibodies
- Alopecia Areata
- Antibody Therapeutics
- Life Sciences
IMA financial model: income statement, cash flow and balance sheet